[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364774-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364774-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mirvetuximab-soravtansine-current-and-future-applications","Mirvetuximab soravtansine - current and future applications","","Ovarian epithelial cancer (OEC), especially high-grade serous carcinoma (HGSC), remains difficult to treat because late diagnosis, high recurrence, and poor survival outcomes persist. Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRα) and has shown promising efficacy in platinum-resistant OEC, with improvements in progression-free survival, response rates, and quality of life in trials including FORWARD I/II, SORAYA, and MIRASOL. FRα is also reported in serous tubal intraepithelial carcinoma (STIC), suggesting potential preventive application alongside risk-reducing bilateral sal pingo-oophorectomy, with broader relevance for other FRα-positive tumors despite cost and access challenges.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mirvetuximab-soravtansine-current-and-future-applications/364774/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mirvetuximab-soravtansine-current-and-future-applications/364774.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical challenge does ovarian epithelial cancer, especially HGSC, present?","Question",{"text":63,"@type":64},"Late-stage diagnosis, high recurrence rates, and poor survival outcomes make OEC, particularly HGSC, a persistent clinical challenge.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does mirvetuximab soravtansine work and where has it shown efficacy?",{"text":68,"@type":64},"MIRV is an antibody-drug conjugate targeting folate receptor alpha (FRα). It has demonstrated promising efficacy in platinum-resistant OEC, particularly in high-FRα-expressing populations, as shown by trials such as FORWARD I/II, SORAYA, and MIRASOL.",{"name":70,"@type":61,"acceptedAnswer":71},"Why might MIRV be considered for serous tubal intraepithelial carcinoma (STIC)?",{"text":72,"@type":64},"FRα is reported as highly expressed in STIC, a non-invasive precursor lesion to HGSC. Although MIRV has not yet been studied for STIC management, the document proposes its potential use to help prevent progression to invasive carcinoma in high-risk patients undergoing risk-reducing bilateral sal pingo-oophorectomy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364774,1790281526,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Kong and Zheng Journal of Hematology & Oncology (2025) 18:33 [https://doi.org/10.1186/s13045-025-01686-2](https://doi.org/10.1186/s13045-025-01686-2)  \nJournal of Hematology & Oncology  \nEDITORIAL Open Access  \nMirvetuximab soravtansine: current and future applications  \nBeihua Kong 1 and Wenxin Zheng2,3,4*  \nAbstract  \nOvarian epithelial cancer (OEC), particularly high-grade serous carcinoma (HGSC), remains a clinical challenge due to its late-stage diagnosis, high recurrence rates, and poor survival outcomes. Mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha (FRα), has demonstrated promising efficacy in platinum-resistant OEC, particularly in high FRα-expressing populations, as evidenced by key clinical trials such as FORWARD I, FORWARD II, SORAYA, and MIRASOL. These trials highlight MIRV’s ability to improve progression-free survival, response rates, and quality of life in advanced disease settings. Emerging data suggest that FRα is also highly expressed in serous tubal intraepithelial carcinoma (STIC), a non-invasive precursor lesion to HGSC. Although MIRV has not yet been studied for STIC management, we propose its potential application in this context to prevent progression to invasive carcinoma, particularly in high-risk populations undergoing risk-reducing bilateral sal pingo-oophorectomy. This novel use could bridge the gap between prevention and treatment, offering a proactive strategy for hereditary cancer management. Furthermore, MIRV’s therapeutic versatility extends to other FRα-positive tumors, such as endometrial and breast cancers, broadening its clinical relevance. Despite challenges such as accessibility and cost, MIRV represents a significant advancement in precision medicine, with potential toredefine prevention and treatment strategies for hereditary and sporadic cancers.  \nKeywords MIRV, Ovarian cancer, High-grade serous carcinoma, BRCA carriers, Serous tubal intraepithelial carcinoma, Risk-reducing bilateral sal pingo-oophorectomy, Cancer prevention strategies  \n*Correspondence:  \nWenxin Zheng  \n[wenxin.zheng@utsouthwestern.edu](wenxin.zheng@utsouthwestern.edu)  \n1Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China  \n2Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA  \n3Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA  \n4Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA  \nOvarian epithelial cancer (OEC) management has relied on platinum-based chemotherapy for over four decades. While this approach has brought significant advancements, a considerable proportion of cancers develop resistance to platinum-based treatments. High-grade serous carcinoma (HGSC), the most lethal subtype of OEC, accounts for the majority of ovarian cancer deaths, with a five-year survival rate below 50% for advanced-stage diagnoses. The introduction of biological agents, such as bevacizumab and PARP inhibitors, has further enhanced therapeutic efficacy, particularly in tumors with BRCA mutations or homologous recombination deficiencies [1]. However, recurrence remains common and is often associated with poor outcomes. This underscores the press-  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the","cbCaieukZeIulRr3","https://ap.wps.com/l/cbCaieukZeIulRr3","pdf",620201,"English","# Abstract\n# The therapeutic role of MIRV in ovarian cancer: clinical applications from key trials","[{\"question\":\"What clinical challenge does ovarian epithelial cancer, especially HGSC, present?\",\"answer\":\"Late-stage diagnosis, high recurrence rates, and poor survival outcomes make OEC, particularly HGSC, a persistent clinical challenge.\"},{\"question\":\"How does mirvetuximab soravtansine work and where has it shown efficacy?\",\"answer\":\"MIRV is an antibody-drug conjugate targeting folate receptor alpha (FRα). It has demonstrated promising efficacy in platinum-resistant OEC, particularly in high-FRα-expressing populations, as shown by trials such as FORWARD I/II, SORAYA, and MIRASOL.\"},{\"question\":\"Why might MIRV be considered for serous tubal intraepithelial carcinoma (STIC)?\",\"answer\":\"FRα is reported as highly expressed in STIC, a non-invasive precursor lesion to HGSC. Although MIRV has not yet been studied for STIC management, the document proposes its potential use to help prevent progression to invasive carcinoma in high-risk patients undergoing risk-reducing bilateral sal pingo-oophorectomy.\"}]","Mirvetuximab soravtansine - current and future applications | PDF",1790158990,13]